The company expects to capture a 10 per cent share in Spain’s $6.34 million meropenem market and consolidate its position in other European countries
Sun Pharma will have exclusive rights to commercialise Nidlegy for indications of skin cancers in the territories of Europe, Australia and New Zealand. Philogen will complete pivotal clinical trials for the product in Europe
Digital success is contingent on the way a company organizes itself around technology
The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility
DKSH has signed an agreement to acquire two ear care brands from Noru Pharma for Australia, New Zealand, and selected markets in Asia.
Sun Pharma will receive from Cassiopea the exclusive right to develop and commercialize WINLEVI in Japan, Australia, New Zealand, Brazil, Mexico and Russia.
Merck is organizing one of the biggest South APAC Virtual Conclave on ‘Next-Gen Labs’ on 20th July.
Infigratinib is not FDA-, Health Canada- or Therapeutics Goods Association-approved for any other indication
Cysoni is a bionic device that paces the heart with real-time respiratory modulation
Subscribe To Our Newsletter & Stay Updated
